Novartis eyes next-gen AAV gene therapies in $1.75B Voyager biobucks pact

In Novartis’ perennial hunt for innovative therapies to bring under its wing, improving on gene therapy has always been kept top of mind. And the Swiss pharma continues to do just that thanks to a new biobucks deal with Voyager Therapeutics worth up to $1.75 billion.